Czarnecka Anna Maria, Obara-Michlewska Marta, Wesół-Kucharska Dorota, Greczan Milena, Kaczor Magdalena, Książyk Janusz, Rokicki Dariusz, Zielińska Magdalena
Department of Neurotoxicology, Mossakowski Medical Research Institute Polish Academy of Sciences, Pawińskiego 5, 02-106 Warsaw, Poland.
Department of Pediatrics, Nutrition, and Metabolic Diseases, Children's Memorial Health Institute, Al. Dzieci Polskich 20, 04-730 Warsaw, Poland.
J Clin Med. 2023 Mar 21;12(6):2411. doi: 10.3390/jcm12062411.
Individuals with inherited hyperammonemias often present developmental and intellectual deficiencies which are likely to be exaggerated by hyperammonemia episodes in long-term outcomes. In order to find a new, systemic marker common to the course of congenital hyperammonemias, we decided to measure the plasma level of S100 calcium-binding protein B (S100B), which is associated with cerebral impairment. Further, we analyzed three mechanistically diverged but linked with oxidative-nitrosative stress biochemical parameters: 3-nitrotyrosine (3-NT), a measure of plasma proteins' nitration; advanced oxidation protein products (AOPP), a measure of protein oxidation; and glutathione peroxidase (GPx) activity, a measure of anti-oxidative enzymatic capacity. The plasma biomarkers listed above were determined for the first time in congenital hyperammonemia. Also, the level of pro- and anti-inflammatory mediators (i.e., IL-12, IL-6, IL-8, TNF-α, IL-1β, and IL-10) and chemokines (IP-10, MCP-1, MIG, and RANTES) were quantified. S100B was positively correlated with plasma ammonia level, while noticeable levels of circulating 3-NT in some of the patients' plasma did not correlate with ammonia concentration. Overall, the linear correlation between ammonia and S100B but not standard oxidative stress-related markers offers a unique perspective for the future identification and monitoring of neurological deficits risk-linked with hyperammonemia episodes in patients with inherited hyperammonemias. The S100B measure may support the development of therapeutic targets and clinical monitoring in these disorders.
患有遗传性高氨血症的个体常常出现发育和智力缺陷,而长期来看,高氨血症发作可能会加剧这些缺陷。为了找到一种先天性高氨血症病程中常见的新型全身性标志物,我们决定测量与脑损伤相关的S100钙结合蛋白B(S100B)的血浆水平。此外,我们分析了三种机制不同但与氧化-亚硝化应激相关的生化参数:3-硝基酪氨酸(3-NT),用于衡量血浆蛋白的硝化程度;晚期氧化蛋白产物(AOPP),用于衡量蛋白氧化程度;以及谷胱甘肽过氧化物酶(GPx)活性,用于衡量抗氧化酶能力。上述血浆生物标志物在先天性高氨血症中首次得到测定。同时,还对促炎和抗炎介质(即白细胞介素-12、白细胞介素-6、白细胞介素-8、肿瘤坏死因子-α、白细胞介素-1β和白细胞介素-10)以及趋化因子(IP-10、单核细胞趋化蛋白-1、γ干扰素诱导单核因子和调节激活正常T细胞表达和分泌因子)的水平进行了定量分析。S100B与血浆氨水平呈正相关,而部分患者血浆中显著的循环3-NT水平与氨浓度无关。总体而言,氨与S100B之间的线性相关性,而非标准的氧化应激相关标志物,为未来识别和监测遗传性高氨血症患者高氨血症发作相关的神经功能缺损风险提供了独特视角。S100B测量值可能有助于这些疾病治疗靶点的开发和临床监测。